85 related articles for article (PubMed ID: 22247028)
21. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
Coban S; Idilman R; Erden E; Tüzün A
Hepatogastroenterology; 2011; 58(109):1301-6. PubMed ID: 21937399
[TBL] [Abstract][Full Text] [Related]
22. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
[TBL] [Abstract][Full Text] [Related]
23. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
[TBL] [Abstract][Full Text] [Related]
24. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
25. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
26. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
27. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
[TBL] [Abstract][Full Text] [Related]
28. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
29. [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].
Saludes Montoro V; Ausina Ruiz V; Martró Català E
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():51-8. PubMed ID: 22305670
[TBL] [Abstract][Full Text] [Related]
30. Genetic factors and hepatitis C virus infection.
Thompson AJ
Gastroenterology; 2012 May; 142(6):1335-9. PubMed ID: 22537440
[No Abstract] [Full Text] [Related]
31. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
32. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
33. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
Toyoda H; Kumada T; Tada T; Murakami Y
J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
[TBL] [Abstract][Full Text] [Related]
34. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
Stättermayer AF; Stauber R; Hofer H; Rutter K; Beinhardt S; Scherzer TM; Zinober K; Datz C; Maieron A; Dulic-Lakovic E; Kessler HH; Steindl-Munda P; Strasser M; Krall C; Ferenci P
Clin Gastroenterol Hepatol; 2011 Apr; 9(4):344-350.e2. PubMed ID: 20728570
[TBL] [Abstract][Full Text] [Related]
35. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
37. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.
Dzekova-Vidimliski P; Nikolov IG; Matevska-Geshkovska N; Mena S; Rostaing L; Dimovski A; Sikole A
Ren Fail; 2015 Aug; 37(7):1180-4. PubMed ID: 26156685
[TBL] [Abstract][Full Text] [Related]
38. IL28B: A new wager in the skyline of hepatitis C virus infection.
Mangia A
Dig Liver Dis; 2011 Mar; 43(3):177-9. PubMed ID: 21237729
[No Abstract] [Full Text] [Related]
39. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
40. IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Lalezari J; Box T; O'Riordan W; Mehra P; Nguyen T; Poordad F; Dejesus E; Kwo P; Godofsky E; Lawrence S; Dubuc-Patrick G; Chen J; McCarville J; Pietropaolo K; Zhou XJ; Sullivan-Bólyai J; Mayers D
Antivir Ther; 2013; 18(6):755-64. PubMed ID: 23439365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
